Tempus AI shares jump as Q3 revenue beats expectations and company raises full-year outlook
Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY and beating estimates. Adjusted earnings were $0.07 per share, ahead of expectations. The company raised its full-year revenue forecast to $1.60B-$1.61B, up from $1.59B. Growth was driven by diagnostics and data applications, with oncology unit growth accelerating to 32%. Tempus also announced progress in data licensing, regulatory clearances, and expansion plans.
How this was made
The 30-second read
Why it matters
The earnings beat and raised outlook suggest stronger demand for its diagnostic and data services, potentially expanding market share.
Market read
The earnings surprise and guidance lift are likely to drive short‑term buying interest and may influence related health‑tech stocks.
What to watch
Potential integration risks from the Personalis acquisition and regulatory timelines for new products.
Background
Tempus AI is a Nasdaq‑listed healthcare technology firm focusing on diagnostics, data licensing, and AI‑driven precision medicine.
Ticker impact
Tempus AI reported Q3 revenue of $411.5M beating estimates and raised full-year guidance, driving a ~10% share jump.
upward pressure as the market prices in the revenue beat and higher guidance
The company delivered better-than-expected revenue and adjusted earnings, and lifted its 2026 revenue outlook, which typically fuels buying interest.
Market effects
The strong results may boost sentiment for the broader healthcare technology and precision medicine sector.
U.S. biotech and health‑tech stocks could see modest gains following the news.
International investors tracking AI‑driven health platforms may adjust exposure to similar companies.
Counterpoint
If the guidance upgrade is already priced in, the stock could face a short‑term pullback.
Key entities
- companyTempus AI
Healthcare technology firm reporting Q3 results.
- executiveEric Lefkofsky
Founder and CEO of Tempus AI.
